Contineum Therapeutics, Inc. Class A Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Yeah. I think it changes the pace of innovation now. We have several compounds that are being developed across mechanisms that we see.

in U.S. and European companies. For us, we see it as a potential advantage. There is the opportunity for additional BD, as you said. As we look to continue to expand our portfolio, we can look towards China and potentially more rational cost metrics around there as well. It also gives us an opportunity in the future to potentially find additional partners for the Asian regions.

We do. The main focus on this is cost efficiency and being able to generate data in a much more efficient manner. For instance, we can generate phase II data sets from our competitors and be able to evaluate that in a much more rapid fashion than had we were building spreadsheets for that, as well as around competitive intelligence and investor interactions and things like that. We see this as a tool for efficiency and ability to reduce costs. We are not using this to synthesize molecules or anything like that. We are very focused on the biology and the team that we have that has been able to generate our portfolio since our inception.

By and large, FDA. We're an early-stage company. We're in the clinic. Obviously, we lean on FDA for guidance for study conduct. It is really the key regulator that we focus on in getting the study up and running.

Sure. We recently put out data or a press release with our partner, Johnson & Johnson, for PIPE-307. This program or this compound was in a phase IIa study focused on MDD and really looking into the cholinergic thesis of depression. A well-controlled study, over 100 patients. Unfortunately, like a lot of MDD studies, we missed on the primary endpoint. J&J has been a fantastic partner through this, and as we communicated in the press release, they are investigating pre-specified exploratory endpoints. We don't have any data to speak about today, but we're looking forward to getting more information from J&J and seeing what the next steps, if any, in the development program of PIPE-307 will be.

Yeah. I think that it is more meaningful than it sounds like on paper. If you look at the patient population with IPF, generally 65 to 85-year-old patients, infirm, a lot of comorbidities, as well as additional treatments that are on their treatment schedule. So having a dose titration adds complexity to their treatment. It potentially leads to additional doctor's visits and things like that. To be able to identify in advance a compound that can be at its starting dose from the very beginning leads to convenience, and I think in this patient population, that is not lip service. That is something that is meaningful in their adherence and ability to address their disease with 791.